Rene Nunez, MD

Safety Profile of Adjunctive Pimavanserin in the ENHANCE Study, a Phase 3 Trial for the Potential Treatment of Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment

Many patients with schizophrenia do not respond fully to antipsychotic treatment despite adherence. Evidence supporting polypharmacy is limited and adding another antipsychotic is associa...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

I-Yuan Liu , MSc;

Rene Nunez , MD;

Ramzey Odetalla , PA, MSc;

Mohammed Bari , MD;

Istvan Bitter , MD, PhD, DSc;

Peter Feldman , PhD;

10/08/2020

Depression in Parkinson`s Disease: Investigations of Pimavanserin, a Selective 5-HT2A Receptor Antagonist/Inverse Agonist

Depression occurs in 30–50% of Parkinson’s disease (PD) patients, yet no drugs are approved specifically to treat PD patients with depressive symptoms. Few clinical studies have been cond...

Rene Nunez , MD;

Maurizio Fava , MD, PhD;

Daryl DeKarske , MPH;

Lori Jacobi , BA;

Bruce Coate , MPH;

Keith Liu , PhD;

Susan Legacy , MD;

Bryan Dirks , MD, MSc, MBA;

10/08/2020